trial

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCTId NCT00136760
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 57 (actual)
Sponsored by Brown University
Primary completion 2009-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
57 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Double
Start
2003-09
Primary completion
2009-03
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
Bupropionnon-contingent reinforcement plus bupropion

Sponsors

Brown UniversityLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Jennifer Tidey, PhDPrincipal Investigator

Sites

1 total
Providence, United States

Linked catalysts

1
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia — primary completion2009-03

Facts & assertions

4 sourced
Enrollment
57
Phase
PHASE2
Primary Completion Date
2009-03
Status
COMPLETED
relationships
The graph out of here
drug
Bupropion
drug
non-contingent reinforcement plus bupropion
drug
lead_sponsor
Brown University
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Tobacco Use Disorder
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Tobacco Use Disorder
indication
investigator
Jennifer Tidey, PhD
person